…”Diagnostics division to help drugmaker tailor treatments.”
Eli Lilly has created a new division to produce tests that will “winnow out the patients most likely to benefit from a Lilly drug.” This new concept of “personalized medicine” recognizes the reality that most drugs work in only about 1/3 of the patients who take them. These new tests will help Lilly identify the subgroups of patients who will benefit the most and at what dose. The diseases that this new Lilly division will be focusing on are Cancer and Alzheimer’s.
Will there be a trend for the life sciences industry that will push pharma companies to develop diagnostic tests alongside their experimental drugs? Terry Hisey, leader of the US life sciences practice, Deloitte Consulting, believes there will be.
